research use only

Deruxtecan Topoisomerase I Inhibitor

Cat.No.S9795

Deruxtecan is an ADC drug-linker conjugate composed of the cleavable glycine–glycine–phenylalanine–glycine tetrapeptide-based linker, a self-immolative amino methylene spacer, and a novel topoisomerase 1 inhibitor payload that is a derivative of exatecan (DX-8951).

Jump to

Quality Control

Batch: S979501 DMSO]100 mg/mL]false]]]false]]]false Purity: 99.86%
99.86

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (96.7 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 1034.05 Formula

C52H56FN9O13

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1599440-13-7 -- Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-19)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07553390 NOT_YET_RECRUITING
Breast Cancer
M.D. Anderson Cancer Center
2026-10-01 PHASE1
NCT07060807 RECRUITING
Breast Neoplasms
Merck Sharp & Dohme LLC
2025-07-21 PHASE3
NCT07578116 NOT_YET_RECRUITING
Anatomic Stage IV Breast Cancer AJCC v8; Metastatic HER2-Positive Breast Carcinoma; Oligometastatic Breast Carcinoma
SWOG Cancer Research Network
2027-03-09 PHASE3
NCT06643585 RECRUITING
Breast Cancer
Prof. Wolfgang Janni
2025-04-22 PHASE3
NCT07022483 RECRUITING
Endometrial Cancer
Daiichi Sankyo
2025-09-30 PHASE3
NCT07776691 NOT_YET_RECRUITING
Ovarian Cancer; Ovarian Neoplasms; Peritoneal Cancer; Fallopian Tube Cancer
Merck Sharp & Dohme LLC
2026-09-22 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.